The DOI matches its Crossref record.
Ischemic Nephropathy: Where Are We Now?
Abstract
Identification and reversing the loss of kidney function beyond occlusive disease of the renal arteries poses a major clinical challenge. Recent studies indicate that atherosclerotic renal artery stenosis develops as a function of age and is commonly associated with other microvascular disease, including nephrosclerosis and diabetic nephropathy. The risks of renal artery stenosis are related both to declining kidney function and to accelerated cardiovascular disease, with increased morbidity and mortality. Newer drugs, including agents that block the renin-angiotensin system, have improved the level of BP control for renovascular hypertension. Progressive renovascular disease during medical therapy can produce refractory hypertension, congestive heart failure, and renal failure with tubulointerstitial fibrosis. Recent studies indicate a complex interplay of oxidative stress, endothelial dysfunction, and activation of fibrogenic cytokines as a result of experimental atherosclerosis and renal hypoperfusion. Advances in imaging and interventional devices offer major new opportunities to prevent progressive loss of kidney function. Recent series indicate that although 25 to 30% of patients with impaired renal function can recover glomerular filtration after revascularization, many have no apparent change in kidney function and 19 to 25% experience a significant loss of kidney function, in some cases as a result of atheroemboli. To select patients who are most likely to benefit from vascular intervention, clinicians should understand the pathophysiology of developing ischemic nephropathy and the potential hazards of revascularization in the setting of diffuse atherosclerotic disease. Further research should be directed toward identification of critical disease, regulation of fibrogenesis, and the interaction with other atherosclerotic processes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Aronow, W. S., Fleg, J. L., Pepine, C. J., Artinian, N. T., Bakris, G., Brown, A. S., Ferdinand, K. C., Forciea, M. A., Frishman, W. H., Jaigobin, C., et al. (2011) · Circulation · doi:10.1161/cir.0b013e31821daaf6 · Cited by 614
ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly
Aronow, W. S., Fleg, J. L., Pepine, C. J., Artinian, N. T., Bakris, G., Brown, A. S., Ferdinand, K. C., Ann Forciea, M., Frishman, W. H., Jaigobin, C., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.01.008 · Cited by 514
Renovascular Hypertension and Ischemic Nephropathy
Garovic, V. D., & Textor, S. C. (2005) · Circulation · doi:10.1161/circulationaha.104.492348 · Cited by 296
Self-citationCollagen‐Targeted MRI Contrast Agent for Molecular Imaging of Fibrosis
Caravan, P., Das, B., Dumas, S., Epstein, F. H., Helm, P. A., Jacques, V., Koerner, S., Kolodziej, A., Shen, L., Sun, W., et al. (2007) · Angewandte Chemie International Edition · doi:10.1002/anie.200700700 · Cited by 268
Velliquette, R. A., O'Connor, T., & Vassar, R. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.2350-05.2005 · Cited by 254
Metadata
- Authors
- Textor, S. C.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2004-08
- Volume
- 15
- Issue
- 8
- Pages
- 1974-1982
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W2155932610
- Cited by
- 160
- References
- 0
- FWCI
- 10.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ischemic Nephropathy: Where Are We Now? https://app.cochat.ai/papers/10.1097/01.asn.0000133699.97353.24
- The paper
- Textor, S. C. (2004). Ischemic Nephropathy: Where Are We Now? Journal of the American Society of Nephrology. https://doi.org/10.1097/01.asn.0000133699.97353.24
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.